Madrigal Pharmaceuticals Inc

1MDGL

Company Profile

  • Business description

    Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

  • Contact

    200 Barr Harbor Drive
    Suite 200, Four Tower Bridge
    West ConshohockenPA19428
    USA

    T: +1 267 824-2827

    E: [email protected]

    https://www.madrigalpharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    528

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,365.7024.700.30%
CAC 407,593.8738.000.50%
DAX 4022,496.9871.150.32%
Dow JONES (US)40,669.36141.740.35%
FTSE 1008,492.342.51-0.03%
HKSE22,119.41111.300.51%
NASDAQ17,446.3414.98-0.09%
Nikkei 22536,452.30406.921.13%
NZX 50 Index12,148.60245.292.06%
S&P 5005,569.068.230.15%
S&P/ASX 2008,145.6019.400.24%
SSE Composite Index3,279.037.62-0.23%

Market Movers